| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Neurology (Drs. Furneaux and Posner) and Medicine (Hematology Service) (Dr. Reich), Memorial Sloan-Kettering Cancer Center, and the Department of Neurology, Cornell University Medical College, New York, NY.
We measured the activity of 2 highly specific autoantibodies (anti-Yo associated with paraneoplastic cerebellar degeneration and anti-Hu associated with paraneoplastic sensory neuronopathy-encephalomyelitis) in simultaneously procured samples of serum and CSF of 18 patients. We also measured the effect of plasma exchange on autoantibody activity in serum and CSF of 6 patients. In 11 patients with paraneoplastic cerebellar degeneration, the CSF/serum ratio of anti-Yo antibody varied between 0.74 and 63, with 8 of 11 patients having ratios substantially greater than 1. In 7 patients with paraneoplastic sensory neuronopathy-encephalomyelitis, the CSF/serum ratio of anti-Hu antibody varied from 0.6 to 44, with 6 of 7 patients having ratios greater than 1. Plasmapheresis reduced the level of the autoantibody in serum without affecting that in the CSF in 5 of 6 patients. These data indicate that autoantibodies in paraneoplastic syndromes are produced in the CNS. This is consistent with the hypothesis of autoimmunity as the pathogenic mechanism. Plasmapheresis failed to effectively remove the antibody from the CNS.
Address correspondence and reprint requests to Dr. Jerome B. Posner, Department of Neurology, 1275 York Avenue, New York, NY 10021.
Supported in part by NS 26044 NINDS.
Presented in part at the 41st annual meeting of the American Academy of Neurology, Chicago, IL, April 1989.
Received June 21, 1989. Accepted for publication in final form December 26, 1989.
This article has been cited by other articles:
|
|
 |
|
  J. B. Posner Paraneoplastic opsoclonus/myoclonus: B cells, T cells, both, or neither? Neurology, May 11, 2004; 62(9): 1466 - 1467. [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Darnell and J. B. Posner Paraneoplastic Syndromes Involving the Nervous System N. Engl. J. Med., October 16, 2003; 349(16): 1543 - 1554. [Full Text] [PDF]
|
|
|
|
 |
|
 T Tani, Y-S Piao, S Mori, N Ishihara, K Tanaka, K Wakabayashi, and H Takahashi Chorea resulting from paraneoplastic striatal encephalitis J. Neurol. Neurosurg. Psychiatry, October 1, 2000; 69(4): 512 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. King RNA-binding analyses of HuC and HuD with the VEGF and c-myc 3'-untranslated regions using a novel ELISA-based assay Nucleic Acids Res., April 1, 2000; 28(7): e20 - e20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Keime-Guibert, F Graus, A Fleury, R Rene, J Honnorat, P Broet, and J-Y Delattre Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone J. Neurol. Neurosurg. Psychiatry, April 1, 2000; 68(4): 479 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Okano, W.-Y. Park, J. P. Corradi, and R. B. Darnell The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival Genes & Dev., August 15, 1999; 13(16): 2087 - 2097. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. O. Dalmau and J. B. Posner Neurological Paraneoplastic Syndromes Neuroscientist, November 1, 1998; 4(6): 443 - 453. [PDF]
|
|
|
|
|
|
R D VOLTZ, J B POSNER, J DALMAU, J B POSNER, J DALMAU, and F GRAUS Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour J. Neurol. Neurosurg. Psychiatry, August 1, 1997; 63(2): 133 - 136. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Erlington Review paper: The Lambert-Eaton myasthenic syndrome Palliative Medicine, January 1, 1992; 6(1): 9 - 17. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
